BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Hepion Pharmaceuticals, Inc. HEPA
13 fiscal years on record · USD · FY2025 reported · SEC filings only
$-8.3M
Growth
—
Revenue, FY2025 · full 13-year series below
Revenue $M
Net income $M
FY2023 · Revenue 0.0 · Net income -48.9
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
FY2025 · ROE -2058.6%
Each USD of equity lost 2059 cents this year.
The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | · | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −0.88 | −107.35 | −616.07 | −11.90 | −0.47 | −2.10 | −6.11 | −97.35 | · | −2.41 | −0.63 | −1.02 | −0.41 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −2058.6 | −487.0 | −171.3 | −59.1 | −49.0 | −72.5 | −81.2 | −348.2 | · | −287.0 | −714.7 | −5672.2 | · |
| Shares out B | 0.01 | 0.00 | 0.00 | 0.00 | 0.08 | 0.03 | 0.00 | 0.00 | 0.01 | 0.08 | 0.03 | 0.02 | 0.02 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 51 reconciliationsAUDITED
Reconciled in 13 of 19 fiscal years. 25 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013